Boulder biotech firm raises $38M

archerDX

Screenshot of the ArcherDX website.

Boulder-based biotechnology company ArcherDX has raised $37.6 million in a recent funding round, according to a Form D SEC filing.

Boulder Ventures and Virginia-based PBM Capital Group led the round, according to a company release. Boston-based Longwood Fund and New York-based Peierls Foundation also participated in the round, which included 31 individual investors.

This is the first lump of funding for the company, according to SEC filings.

Founded in 2013, ArcherDX works in cancer research, making products to identify genetic mutations for cancer or immunology diagnosis. The company said it would use the funding to expand into commercial markets both in the U.S. and internationally.

archerDX

Screenshot of the ArcherDX website.

A company that works in cancer research plans to use its eight-figure funding round to expand into commercial markets.

You must be a member to access BusinessDen's exclusive reporting.

Your subscription has expired. Renew now by choosing a subscription below!

For more information, head over to your profile.

Profile


SUBSCRIBE NOW

TERMS OF SERVICE:

ALL MEMBERSHIPS RENEW AUTOMATICALLY. YOU WILL BE CHARGED FOR A 1 YEAR MEMBERSHIP RENEWAL AT THE RATE IN EFFECT AT THAT TIME UNLESS YOU CANCEL YOUR MEMBERSHIP BY LOGGING IN OR BY CONTACTING AARON@BUSINESSDEN.COM.

ALL CHARGES FOR MONTHLY OR ANNUAL MEMBERSHIPS ARE NONREFUNDABLE.

EACH MEMBERSHIP WILL ONLY FUNCTION ON UP TO 3 MACHINES. ACCOUNTS ABUSING THAT LIMIT WILL BE DISCONTINUED.




Return to Homepage

24822

Leave a Reply

Your email address will not be published.